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Abstract
Background: Pre-exposure prophylaxis (PrEP) has been shown to be highly effective for the prevention of HIV in clinical trials
and demonstration projects, but PrEP uptake and adherence outside of these settings in the United States has been limited. Lack
of knowledge and willingness of health care providers (HCPs) to prescribe PrEP is an important barrier to implementation.
Objective: The objective of this study was to describe and examine the feasibility and acceptability of a PrEP Optimization
Intervention (PrEP-OI) targeted at HCPs. The ultimate purpose of this intervention was to increase PrEP uptake, adherence, and
persistence among those at risk for HIV acquisition.
Methods: This intervention included the following: (1) a Web-based panel management tool called PrEP-Rx, which provides
comprehensive HIV risk assessment, automates reminders for follow-up, and reports patients’ history of PrEP use; and (2)
centralized PrEP coordination by a clinical support staff member (ie, the PrEP coordinator) who can identify individuals at risk
for HIV, provide medical insurance navigation, and support multiple HCPs. Feasibility was evaluated based on HCPs’ ability to
log in to PrEP-Rx and use it as needed. Acceptability was assessed via individual formative qualitative interviews with HCPs
after 1 month of the intervention.
Results: The intervention was feasible and acceptable among HCPs (N=6). HCPs identified system-level barriers to PrEP
provision, many of which can be addressed by this intervention. HCPs noted that the intervention improved their PrEP knowledge;
increased ease of PrEP prescription; and was likely to improve patient engagement and retention in care, enhance communication
with patients, and improve patient monitoring and follow-up.
Conclusions: Given the critical role HCPs serve in disseminating PrEP, we created an easy-to-use PrEP optimization intervention
deemed feasible and acceptable to providers. Further research on this tool and its ability to impact the PrEP continuum of care is
needed.
(JMIR Formativ Res 2018;2(1):e2)   doi:10.2196/formative.8623
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Introduction
Pre-exposure prophylaxis (PrEP) has been shown to be highly
effective for the prevention of HIV in randomized clinical trials
[1-6] and demonstration projects [7-9], but PrEP uptake in the
United States has not been concomitant with need [10-12].
Despite data indicating nearly 80,000 individuals starting PrEP
by the end of 2015 [13], the US Centers for Disease Control
and Prevention (CDC) estimates that there are over 1.2 million
adults in the United States at substantial risk for HIV acquisition
[14]. Identified barriers to PrEP implementation include the
individual’s awareness of and willingness to take PrEP and their
access to health care and the knowledge and willingness of
health care providers (HCPs) to prescribe PrEP [10,15-20]. The
prevention of new HIV infections remains a critical public health
priority, and PrEP is an essential [21], yet underused, component
of the HIV prevention toolkit. As HCPs are important
gatekeepers for biomedical HIV prevention efforts in clinical
settings and provider knowledge and self-efficacy are important
predictors of offering testing [22,23] and prevention modalities,
HCPs require support and guidance to optimize the clinical and
public health impact of PrEP.
Numerous surveys have been conducted to evaluate HCPs’
knowledge of PrEP, barriers to prescribing PrEP, and real-world
challenges [10,12,19,20,24-28]. In one survey of Emerging
Infections Network members in the United States and Canada
[12], only 9% had provided PrEP, and despite the availability
of comprehensive guidelines from the CDC [29-32], PrEP
practices were variable. When physicians who had indicated
that they would not provide PrEP were asked about their barriers
to prescribing this medication, 77% stated that they worried
about adherence and the risk for future resistance, 57% were
concerned about cost and reimbursement issues, 53% did not
want to use potentially toxic drugs in healthy persons, and 53%
felt there was insufficient evidence for the efficacy of real-world
PrEP. A recent paper examined family planning providers’
knowledge of and attitudes toward PrEP [17]. Despite the CDC’s
definition of HIV prevention as a core family planning service,
the authors noted that only 38% correctly defined PrEP, 37%
understood the effectiveness of PrEP, and only 36% of
respondents consulted PrEP guidelines. Most surveys have
concluded that more education, provision of guidelines for
real-world PrEP delivery, and interventions are needed to
provide accurate data and optimize PrEP implementation
[10,12,19,20,24,25,27] nationwide. In a recent national survey
from 2009 to 2015, only 66% of primary care clinicians were
aware of PrEP, although, once defined, 91% indicated a
willingness to prescribe PrEP for patients at risk for HIV and
expressed an interest in being educated further about PrEP [33].
A descriptive report on the early experiences with PrEP uptake
and delivery in San Francisco identified the following priority
steps for HCPs to address PrEP delivery barriers and to
maximize public health impact: (1) increase PrEP knowledge
among HCPs and (2) expand PrEP access by training HCPs and
developing tools to facilitate PrEP delivery in clinical practices
[34]. Moreover, based on the framework of the PrEP care
continuum [35], increasing PrEP uptake will require HCP
education, tools to assess sexual risk, and systems to minimize
provider burden. On the basis of these suggestions, innovative
and effective approaches are needed to support PrEP
implementation by HCPs regardless of their level of experience.
Therefore, we sought to develop a PrEP Optimization
Intervention (PrEP-OI) targeted at HCPs with the goal of
ultimately improving the PrEP care continuum. PrEP-OI
includes the following: (1) an integrated Web-based panel
management tool, called PrEP-Rx, which provides structured
HIV risk assessment for individuals of all genders and HIV risk
factors, automates reminders for laboratory testing and follow-up
appointments, and reports patients’ current and history of PrEP
use; and (2) centralized PrEP coordination overseen by a clinical
support staff member (referred to as the PrEP coordinator) who
can support multiple HCPs and identify individuals at high risk
for HIV through various methods, including structured
behavioral surveys, direct patient contact, or by reviewing
registries for sexually transmitted infections. Here we describe
PrEP-OI and the results of a pilot study to examine its feasibility
and acceptability among HCPs prescribing PrEP.
Methods
We developed PrEP-OI (PrEP-Rx and PrEP coordinator) with
direct input from HCPs and conducted a pilot study over 1
month to examine intervention feasibility and acceptability in
a San Francisco clinic offering PrEP. Our interdisciplinary team
consisted of HIV researchers from the University of California,
San Francisco (UCSF), Center for AIDS Prevention Studies
(CAPS), HIV clinicians from San Francisco General Hospital’s
HIV clinic (Ward 86), and technology design/development
experts (the Information Services Unit) from UCSF. We
received funding from the UCSF Center for AIDS Research
(grant number P30 AI027763) to design and develop PrEP-Rx
and received approval from the UCSF Institutional Review
Board to conduct our pilot study.
Description of the Pre-Exposure Prophylaxis
Optimization Intervention
PrEP-Rx was created using a Salesforce backend, with the
potential to integrate with electronic health record (EHR) for
laboratory values and demographic data, and a Qualtrics survey
was used to assess risk among potential PrEP users (Figure 1).
The hypothetical clinic workflow (Figure 2) demonstrated the
need for 3 main components: (1) a mechanism to
comprehensively assess HIV risk for individuals of all genders
and HIV risk factors; (2) automated reminders for upcoming
and overdue laboratory monitoring and follow-up visits to assess
adherence and adverse effects and to perform risk reduction
counseling; and (3) a website with PrEP educational material
(eg, guidelines, publications, conference proceedings) for the
ongoing education and training of HCPs.
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Figure 1. Architecture of PrEP-Rx.
Figure 2. Hypothetical Clinic Work Flow.
A risk assessment questionnaire was created by Drs Saberi and
Scott using available published data to capture an individual’s
risk profile. The CDC risk index [36] was used for men who
have sex with men (MSM). With input from behavioral risk
assessment experts at the UCSF Transgender Centers of
Excellence and CAPS, we modified this assessment to include
questions specific for transgender men and women. Next, using
data from the CDC guidelines, we added risk assessment
questions for heterosexual men and women [29], and with
information from a publication by Smith et al [37], we added
questions regarding injection drug use (IDU) risk. In the absence
of a uniform rating scale for MSM, IDU, and heterosexual sex,
we modified this tool to include 3 tiers of risk: (1) low, (2)
medium, and (3) high (Table 1). The CAPS Community
Advisory Board reviewed all questions for clarity and cultural
appropriateness. We programed this questionnaire into Qualtrics
and integrated the responses with the Salesforce database (Figure
1).
The provider dashboard is a method of summarizing patients’
pertinent information (ie, HIV risk category, prior PrEP use,
and laboratory data) in one simple format for the HCP (Figure
3). This dashboard consists of 4 components (in separate boxes)
for each patient: (1) demographics (including patient’s name,
medical record number, date of birth, and telephone number);
(2) PrEP timeline(s) (summary of current and prior PrEP periods
of use, including dates of initial PrEP appointment, follow-up
appointments, laboratory visits, and reasons for prior PrEP
discontinuations, if applicable); (3) risk categories (summary
of risk based on the risk assessment questionnaire and the risk
assessment category); and (4) laboratory data required for PrEP
initiation (including the last 2 laboratory results on file). The
HCP can type a note in the PrEP Timeline and Risk sections to
reference in future follow-up visits.
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Table 1. Three tiers of HIV risk in PrEP Rx.
Heterosexual sexInjection drug useMen who have sex with menRisk
High risk 1.1.1. 10 opposite-sex sex partners in the past
6 months
Age: <30 yearsAge: 18-28 years
2. 2.10 male sex partners in the past 6
months
If NOT in methadone maintenance
program in the last 6 months 2. (For men only) Any sex without a
condom with a woman at high risk for
HIV (eg, IDUa) or HIV+ or HIV status
unknown
3.3. If composite injection score (inject
heroin, inject cocaine, share cooker,
share needles, visit shooting gallery)
>1
Any receptive anal sex with a man
without a condom
4. >1 HIV+ or HIV status unknown male
partner in the past 6 months 3. (For women only) Any sex without a
condom with a partner at high risk for
HIV (eg, IDU or bisexual male) or
HIV+ or HIV status unknown
4.5. If 2 or more medium-risk factorsAny commercial sex work in the past
6 months
6. Any sexually transmitted infection
7. If 2 or more medium-risk factors 4. Any commercial sex work in the past
6 months
5. If 2 or more medium-risk factors
Medium risk 1.1.1. 6-10 opposite-sex sex partners in the
past 6 months
Age: 30-39 yearsAge: 29-40 years
2. 2.If composite injection score (inject
heroin, inject cocaine, share cooker,
share needles, visit shooting gallery)
=1
6-10 male partners in the past 6 months
2. Any sexually transmitted infection
3. 1 HIV+ or HIV status unknown male
partner in the past 6 months
4. Use of methamphetamine in the past
6 months
5. >1 insertive anal sex without a condom
with a man who was HIV+ or HIV
status unknown unknown
6. Heavy alcohol use (5-7 days a week
and drinks per day ≥4 or 1-7 days per
week and ≥6 drinks per day)
7. Use of cocaine/crack or poppers
Everyone elseEveryone elseEveryone elseLow risk
aIDU: injection drug use.
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Figure 3. Provider Dashboard.
The PrEP coordinator is responsible for supporting both HCPs
and patients in this intervention. The PrEP coordinator enters
the patient’s medical record number into PrEP-Rx, which pulls
demographic information and laboratory data from the clinic’s
EHR (Figure 1). During the patient’s visit with the PrEP
coordinator, he/she is handed a tablet to respond to the risk
assessment questionnaire. On the basis of the patient’s responses,
HIV risk categories are generated and displayed on the provider
dashboard, along with the patient’s demographics, laboratory
data, and current and/or prior PrEP history (ie, PrEP timeline).
The patient then attends an appointment with the HCP where
they can discuss the patient’s risk and laboratory test results,
desire to initiate PrEP (which can be recorded in the notes
section of the provider dashboard), and any questions or
concerns about PrEP. On the basis of the PrEP prescription date,
PrEP-Rx auto-generates a list of dates for follow-up laboratory
tests and appointments based on CDC guidelines. As a result,
the PrEP coordinator receives notifications via emails about
upcoming or past due visits, allowing her/him to notify the
patient and mark these tasks as “done” upon completion.
Finally, to create a system for the ongoing education of HCPs,
we created the PrEP-Rx website to host the PrEP knowledge
base. The purpose of the knowledge base is to provide access
to the most recent publications, ongoing PrEP research, and
conference proceedings. All components of PrEP-Rx are built
in an environment that is compliant with the Health Insurance
Portability and Accountability Act and meet the highest level
of security requirements.
Pilot Study
We conducted a 1-month pilot study to evaluate the feasibility,
acceptability, and usability of PrEP-OI at a publicly funded
safety-net clinic in San Francisco offering PrEP. Feasibility was
evaluated based on HCPs’ ability to log in to PrEP-Rx and use
it as needed (based on Google Analytics). The acceptability of
PrEP-Rx was assessed in one-on-one formative qualitative
interviews with providers who had used PrEP-Rx for 1 month
along with PrEP coordination. The main goal of these formative
interviews was for providers to give feedback and to assist us
in optimizing PrEP-Rx through our iterative design. Questions
included the following: (1) experiences with PrEP-Rx
(ease/difficulty with initial login and navigation, glitches, and
opinions on its interface), (2) how it may have impacted the
HCP’s knowledge and ability to prescribe PrEP, (3) experience
with the PrEP coordinator, (4) what aspects of PrEP-OI HCPs
found favorable and unfavorable, (5) how this intervention can
be further streamlined to fit within their workflow, (6) whether
they would recommend this intervention to their peers, and (7)
whether they would consider continuing to use it in their clinical
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practice. Usability was evaluated based on a modified System
Usability Scale [38], which evaluates the HCP’s desire to use
PrEP-Rx, complexity/ease of use, need for technical support,
confidence with use, and speed of learning to use PrEP-Rx.
Items are scored on a scale of 1-5 (strongly disagree to strongly
agree) and summed to provide an overall score ranging from 0
to 100.
Formative qualitative interviews were audio-recorded,
transcribed verbatim, and summarized by the first author. Broad
themes were then identified and entered into a matrix using
Microsoft Excel where columns and rows represented themes
and participants, respectively, to facilitate data analysis and the
identification of patterns in the distribution of themes [39]. The
first author categorized each interview using this matrix, and
themes were discussed with the second, third, and last authors.
On the basis of these discussions, modifications to the design
of PrEP-Rx were identified.
Results
A total of 6 HCPs gave us feedback on their experience with
PrEP-OI after 1 month of use in December 2016. HCPs were
physicians 83% (5/6) and nurse practitioners 17% (1/6), female
67% (4/6), white 50% (3/6), working in an HIV clinic 100%
6/6), with a mean of 13 years (range 4-17 years) of experience
providing care for individuals living with HIV. Approximately
67% (4/6) and 33% (2/6) provided HIV care for 20-49 and
greater than or equal to 50 patients living with HIV, respectively.
Of the HCPs, 2 (33%) did not have an active PrEP patient at
the time of the interview, 3 (50%) were providing PrEP to 1-9
patients, and 1 (17%) was providing PrEP to 10-19 patients.
Using the System Usability Scale, HCPs gave PrEP-Rx a score
of 94.6 (standard deviation 6.4). This meant that they strongly
agreed that they (1) would like to use PrEP-Rx, (2) thought it
was easy to use and did not need to learn a lot before getting
started, (3) found the functions well integrated and consistent
with the goals of the project, and (4) felt confident using
PrEP-Rx without technical support.
The initial meeting with each HCP to describe the purpose of
PrEP-Rx, to ensure ability to log in, and to answer any questions
took approximately 20 min. All HCPs stated that their initial
log in was easy and fast and that the use of a single sign-on
service made it easy for them to log in without needing to
remember an additional username and password. Of the
providers, 1 had difficulty with initial log in due to the use of
an old Web browser version. On the basis of Google Analytics,
during the 1 month of use, users had 74 PrEP-Rx sessions, and
the average session duration was 6:08 minutes. None of the
users contacted us during the 1 month of the pilot about inability
to log in, glitches, or problems accessing their dashboard.
In one-on-one formative qualitative interviews, HCPs discussed
barriers that they had experienced in providing PrEP and gave
constructive feedback on improvements to PrEP-Rx. Barriers
were categorized into patient-, system-, and societal-level and
summarized in Table 2. HCPs identified the biggest challenge
as missed medical visits by patients on PrEP.
HCPs stated that the PrEP-Rx tool is easy to use (HCPs #1, #2,
and #3), “clean” (HCPs #1 and #3), “intuitive” (HCP #3),
“soothing” (HCP #6), and organized using “boxes so you know
where to look for stuff” (HCP #1).
...clean, clear, organized in a manner which I expect
to see things, not a lot of wasted space... [HCP #3]
They liked the simple look of PrEP-Rx, stating “I dislike
websites that are too slick” (HCP #2).
HCPs unanimously reported that PrEP-Rx has the potential to
improve their level of information regarding PrEP, capacity for
PrEP provision, and/or motivation to prescribe PrEP. Table 3
summarizes HCPs’ statements of the areas that PrEP-OI could
impact.
HCPs requested the following modifications to PrEP-Rx: (1)
in the Demographics section, the addition of patient’s email
address and a demographics notes section; (2) in the PrEP
Timeline section, addition of the date that the PrEP prescription
was written (if different from the initial PrEP appointment); (3)
in the Laboratory section, the permanent display of the baseline
laboratory values (ie, before PrEP initiation), information about
laboratory normal ranges or cutoffs for PrEP prescription, and
a laboratory notes section; (4) in the Risk Assessment section,
addition of guidance around PrEP medication dosing frequency
and number of refills to prescribe upon PrEP initiation and
availability of the risk assessment questionnaire in Spanish; (5)
on the PrEP-Rx website, addition of pivotal PrEP studies and
educational handouts or information that the HCP can give to
patients to answer questions (eg, what is PrEP and why is it
being prescribed, how is PrEP taken, what to do in case of
intolerance, and who to call in case of emergencies); and (6)
addition of a new section to track PrEP adherence and
persistence.
None of the HCPs had any major concerns regarding the privacy
and security of the data; all wanted to continue using PrEP-Rx,
and would recommend it to other HCPs and for use in other
countries.
I would love to have more opportunity to use it...things
like this will help us overcome a lot of limitations in
our current system, so I'd love to continue using it.
[HCP #6]
I've been thinking in terms of PrEP roll out in places
where Internet access is challenging...so there’s so
much happening in terms of more countries approving
PrEP, like Kenya and South Africa. If you think of,
in terms of clinics that are already so over-burdened,
and what can be helpful for providers, even if it’s a
lay health worker who is asking questions on a tablet
so by the time they get to the provider...I can see it
being translatable on a tablet in other countries. [HCP
#6]
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Table 2. Barriers to the provision of pre-exposure prophylaxis as identified by health care providers.
Example quotesCategory and subcategory
Patient-specific
Uptake in mono-lingual Spanish-speaking patients is very low. It’s a hard concept to grasp
in terms of: “if I’m not sick, why should I take a pill?” [HCPb#1]
Lack of PrEPa information or misinformation, espe-
cially in monolingual Spanish-speaking patients or
immigrants
...for other partners of patients of mine, who have chosen not to start, there is some feeling
of perhaps being at lower risk because of long-term partnerships and no transmission so
far either through suppressed viral load, condoms, or both... [HCP #6]
Patients less concerned about risk of HIV acquisi-
tion due to being in a long-term partnership without
HIV transmission from seropositive partners
...potential PrEP clients are on the highly vulnerable end of the spectrum. Several of them
who were scheduled to see me for PrEP evaluation never showed up and a number, who
showed up for the first visit, never came back for follow-up. [HCP #2]
PrEP nonadherence, nonpersistence, and loss-to-
follow-up possibly due to mental health issues,
substance use, food insecurity, or homelessness
...getting them in to their second visit, one-month visit and three-month visit is challenging.
They are first eager but then follow-up is problematic. It may be due to substance use. [HCP
#4]
System-specific
We have a lot of unknowns...We have a lot challenges from an operational public health
stand point like how do we keep people accessing PrEP regardless of where they are. Every
door should be right door, so people don't lose access to PrEP. [HCP #3]
Fractionated medical coverage, especially in those
on Medi-Cal and with younger patients
So, if someone has insurance, they have to renew it, particularly if they have Medi-Cal, I
believe every 6 months. So, they often will receive a letter and if they don’t respond to that
letter, they’re just dropped. So, they don’t really realize what has happened before it’s too
late. Some pharmacists are great and they’ll figure out a bridge while we figure out the in-
surance, but in many cases people will go without PrEP for weeks to months while we figure
out a way to get the insurance back up. So, there’s the hassle factor of reinitiating PrEP
that for a lot of people is a big barrier. [HCP #3]
...if you're a providers in a primary care center or another clinic, do they address PrEP with
their patients? and I think not in many cases...some of them don’t know about it, even though
it's been available...it’s one more thing you need to deal with and when you have a lot of
things on your plate and you only have 15 minutes in many cases, you’re going to pick the
things you’re responsible for: the high blood pressure and diabetes...how many primary
care providers actually ask their patients if they're sexually active, have a sexual part-
ner...there’s a lot of assumptions made and, unfortunately, it's a topic that if the patient does
not bring up, the provider thinks everything is okay... [HCP #1]
HCPs not addressing PrEP or HIV risk
The first, I supposed, is getting people in for PrEP...identifying people at risk and actually
getting them into clinic. [HCP #4]
Ability to identify and engage people at high risk
for HIV acquisition
I will say that it’s very rare for someone to have tested before they come even though they’ve
usually been given lab orders...but they rarely come in before their first meeting with me...so
there is often a delay, so I’ll say: “...we’ll call you in a day or two...and we’ll send in the
prescription if everything is looking good.” So...there’s a delay and we have to go chasing
them...Usually it’s okay but it would be much more satisfying if we could give them the pre-
scription knowing their results...ideally, they’d do labs in advance and be able to start if
everything looks appropriate... [HCP #4]
Delay in getting laboratory results before PrEP ini-
tiation
Societal-specific
...this woman who couldn’t get PrEP, some of it was because of stigma and also concern
for, “Is this medicine for anything other than HIV if I go to the pharmacy and pick it up?”
[HCP #6]
Stigma associated with being on medications for
HIV
aPrEP: pre-exposure prophylaxis.
bHCPs: health care providers.
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Table 3. Potential impacts of the pre-exposure prophylaxis (PrEP) Optimization Intervention on the provision of PrEP.
Example quotesIntervention component and impact on PrEPa prescribing
PrEP-Rx
...it streamlines all the important elements that you’d want to know for a discussion with the
patient. It lays out things clearly so it’s easy to see all the things in follow-up. Timeline gives
a summary and walks you through the steps and is laid out in a structured way. [HCP #3]
Knowledge base providing quick references and
information related to PrEP
...being able to look at the information on risk and timeline and having patients teed up, is
very helpful and so much easier than current HER...it makes me so much more effective as
a provider of PrEP. [HCP #4]
Ability to provide all necessary data for all patients
on PrEP in 1 comprehensive streamlined format,
resulting in increased ease of PrEP prescription and
being more effective
The survey goes into so much detail that would take a really long time as a provider to go
into and it would be unlikely to get into this exact level of detail without a fairly involved
visit especially for someone you’re meeting for the first time...We’re always focused on time
as providers, so overcoming that hurdle of how many different screens do I need to click
through to figure out...all their labs, trying to have all their follow-up, and really just the
survey being so detailed. That would overcome a lot of the energy to do this in a reasonable
amount of time for the provider and the patient. [HCP #6]
Allowing for the PrEP coordinator to function more
effectively
PrEP coordinator
[the PrEP coordinator] is the “glue” as far as getting the person in and encouraging them
to come in...it is undoable without [the PrEP coordinator]. [HCP #4]
Increasing patient engagement in health care and
retention
...having multiple touch points for the patient can be really helpful...the more likely you are
to get someone engaged and sustained... [HCP #6]
Improving communication between health care
providers and patients
PrEP Rx + PrEP coordinator
...it motivates in as much as it’s linked to the patient. Because for providers that’s where
our motivation is: to keep our patients healthy and happy...I think that thinking about how
this is helping my patients and how this is helping reduce their HIV risk, is a motivation for
me... [HCP #3]
Helping keep patients healthy by improving moni-
toring and follow-up
It makes me capable and motivates me because I know my patients are getting good care
and know when my patients have fallen out of care. [HCP #4]
Reducing loss to follow-up
aPrEP: pre-exposure prophylaxis.
Discussion
We created the PrEP-OI, which includes a clinical staff member
supporting HCPs (ie, the PrEP coordinator) and an easy-to-use
Web-based tool (ie, PrEP-Rx), with guidance from HCPs. We
then conducted a pilot study to examine the feasibility and
acceptability of this intervention among 6 HCPs prescribing
PrEP with varying levels of PrEP experience. The results of our
pilot study reveal that this intervention is feasible to implement
in clinical settings, and acceptable among HCPs regardless of
their level of PrEP experience. Overall, HCPs identified several
system-level barriers to PrEP provision (eg, HCPs not addressing
HIV risk in routine practice, identification and engagement of
people at high risk for HIV acquisition, and insurance
navigation), many of which can be addressed with PrEP-OI.
Additionally, the intervention was noted to improve HCPs’
PrEP knowledge and information and increase ease of PrEP
prescription, and deemed likely to increase patient engagement
and retention in care, improve communication between HCPs
and patients, and improve quality of PrEP monitoring.
HCPs rated PrEP-Rx highly on the System Usability Scale and
had favorable reviews of its look, feel, and functionality. There
were no major privacy concerns, and all HCPs wanted to
continue its use in their clinical practice. HCPs requested several
additions to the Demographics, PrEP Timeline, Risk
Assessment, and Laboratory sections, as well as a new section
on PrEP adherence and additional information for patients and
HCPs on the PrEP-Rx website.
Our intervention was pilot-tested in a clinic that employs panel
management strategies. Panel management is defined as a “set
of tools and processes for population care that are applied
systematically at the level of a primary care panel” [40,41]. It
is an approach to ensure that patients are up-to-date on their
care and can receive additional support if required. Panel
management can involve clinical support staff using chronic
disease registries, EHRs, and other data-reporting tools to
identify missed opportunities for disease prevention and
treatment. These support staff are the liaison between the HCP
and the patient and communicate and reinforce recommendations
from HCPs or guidelines to the patient. Panel management
strategies have been used in many settings to improve rates of
vaccination, bone density screening for the elderly, hypertension
treatment, and so on [42,43]. Successful panel management
programs employ computerized clinical support tools to provide
relevant care reminders, data registries, and performance
feedback [44]. These electronic clinical tools are associated
with improved health care management [45]. In our study, we
leverage panel management strategies including a staff member
(ie, PrEP coordinator) and a clinical support tool (ie, PrEP-Rx)
to serve a goal of enhancing PrEP initiation and appropriate
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monitoring and follow-up. To our knowledge, this is the first
study examining these strategies in the setting of HIV PrEP.
The development of PrEP-OI highlights the importance of joint
efforts between academia, industry, and community partners.
Using the framework of the PrEP care continuum [35], we chose
to focus on the role of the HCP in being educated about PrEP,
screening for high-risk behaviors, prescribing PrEP, and
conducting ongoing monitoring and follow-up with the help of
the PrEP coordinator. The PrEP coordinator is responsible for
verifying patients’ insurance and eligibility status, scheduling
appointments, evaluating HIV risk using the risk assessment
questionnaire, following up with patients, and conducting
medication and adherence counseling. PrEP-Rx is an electronic
tool that provides education for HCPs, allows for the assessment
of HIV risk in a comprehensive manner, tracks monitoring and
follow-up visits, and summarizes details related to HIV risk,
pertinent laboratory results, and patients’ current and/or prior
PrEP use.
Limitations of our study include a small sample of HCPs at a
clinic in a single geographic region over a short timeframe.
Clinicians in this clinic were HIV specialists and received
support from the PrEP coordinator. Therefore, our results may
not be generalizable to other cities or clinics. A randomized trial
of several primary care clinics in the San Francisco Bay Area
to examine PrEP uptake and persistence over longer periods of
time with this PrEP intervention is in progress.
PrEP-OI, including a PrEP coordinator and PrEP-Rx, has the
potential to enhance PrEP uptake, adherence, and persistence
along the PrEP care continuum [35] and improve HCPs’
knowledge and prescribing practices. Studies have highlighted
the cost-effectiveness of PrEP in target populations [46-48];
however, given the high upfront costs, PrEP scale-up may not
be feasible in many settings. Additionally, despite an increase
in PrEP uptake in San Francisco, most recent data indicate that
demand currently exceeds the supply of providers who prescribe
PrEP [49]. Therefore, the automation of risk assessment, risk
calculation, and reminders for monitoring and follow-up in
addition to the assistance of a designated clinic staff to oversee
these efforts and assist with establishment of medical coverage
has the potential to reduce costs associated with clinician time
and clinic resources.
Due to expanding access to Web-based and mobile technologies
for decision support, HCPs are increasingly using online
resources [50]. These technologies have been in the form of
remote monitoring technologies [51], computerized decision
support systems [52], and mHealth technologies (including
geographic information systems) [53]. Many studies have
reported providers’ acceptance of online and mobile
technologies and demonstrated promising results, such as
improved retention in care for their patients. Therefore,
providing support to HCPs is essential for effective PrEP
implementation as they are the supply link for those interested
in initiating PrEP. PrEP-OI has the potential for improving the
efficiency and quality of this “supply” link by assisting HCPs
in prescribing PrEP.
As a next step, we will evaluate the efficacy of PrEP-OI to
increase PrEP prescriptions and PrEP persistence through a
stepped-wedge design among primary care clinics in San
Francisco. Given the need for efficient and targeted identification
of those at high risk for HIV acquisition, establishment of
medical coverage, standardized and comprehensive HIV risk
assessment, efficiency in HCP-patient communication around
HIV risk and PrEP use, and appropriate monitoring and
follow-up, the proposed PrEP-OI has the potential to
significantly enhance the HIV PrEP continuum of care. If
successful, our goal is to implement this intervention in other
health systems, in settings outside of San Francisco, and in
international settings.
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